SIIFIC Wellness Fund Invests in Toregem Biopharma
The SIIFIC Wellness Fund, managed by SIIF Impact Capital, has invested in Toregem Biopharma, a company developing regenerative dental medicine. The investment aims to accelerate clinical development of their antibody drug (TRG035) for congenital anodontia, promoting a shift from prosthetic dentistry to regenerative therapy.
📋 Article Processing Timeline
- 📰 Published: May 27, 2026 at 11:00
- 🔍 Collected: May 31, 2026 at 23:07 (108h 7m after Published)
- 🤖 AI Analyzed: June 2, 2026 at 01:30 (26h 22m after Collected)
The Social Innovation and Investment Foundation (SIIF), in collaboration with SIIF Impact Capital (SIIFIC), announced that the SIIFIC Wellness Fund participated in a third-party allotment of shares by Toregem Biopharma on April 27, 2026. Toregem Biopharma is a drug discovery company aiming to commercialize regenerative dental medicine using an antibody (TRG035) that inhibits the tooth development suppressor USAG-1. Having completed Phase 1 trials in Japan for congenital anodontia, the company seeks to shift dental care from conventional prosthetics to 'curative therapy' that induces natural tooth formation. The investment aligns with the fund's focus on products that provide reliable medical care and encourage positive lifestyles. As congenital anodontia lacks curative treatments until adulthood, this investment is expected to accelerate the clinical development of the world's first tooth regeneration drug, improving patient QOL and contributing to the advancement of dental care. Moving forward, the fund will provide hands-on support and Impact Measurement and Management (IMM) to help realize a world where everyone can chew, speak, and smile with their natural teeth.
FAQ
What is the relevance of this news to the Taiwan market?
As Taiwan faces an aging population, the advancement of dental regenerative medicine could lead to future technological collaborations or market entry opportunities.